↓ Skip to main content

Dove Medical Press

Article Metrics

Selective use of sorafenib in the treatment of thyroid cancer

Overview of attention for article published in Drug Design, Development and Therapy, March 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter
3 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
39 Dimensions

Readers on

mendeley
37 Mendeley
Title
Selective use of sorafenib in the treatment of thyroid cancer
Published in
Drug Design, Development and Therapy, March 2016
DOI 10.2147/dddt.s82972
Pubmed ID
Authors

Fabián Pitoia, Fernando Jerkovich

Abstract

Sorafenib is a multiple kinase inhibitor (MKI) approved for the treatment of primary advanced renal cell carcinoma and advanced primary liver cancer. It was recently approved by several health agencies around the world as the first available MKI treatment for radioactive iodine-refractory advanced and progressive differentiated thyroid cancer. Sorafenib targets C-RAF, B-RAF, VEGF receptor-1, -2, -3, PDGF receptor-β, RET, c-kit, and Flt-3. As a multifunctional inhibitor, sorafenib has the potential of inhibiting tumor growth, progression, metastasis, and angiogenesis and downregulating mechanisms that protect tumors from apoptosis and has shown to increase the progression-free survival in several Phase II trials. This led to the Phase III trial (DECISION) which showed that there was an improvement in progression-free survival of 5 months for patients on sorafenib when compared to those on placebo. Adverse events with this drug are common but usually manageable. The development of resistance after 1 or 2 years is almost a rule in most patients who showed partial response or stabilization of the disease while on sorafenib, which makes it necessary to think of a plan for subsequent therapies. These may include the use of another MKI, such as lenvatinib, the second approved MKI for advanced differentiated thyroid cancer, or include patients in clinical trials or the off-label use of other MKIs. Given sorafenib's earlier approval, most centers now have access to its prescription. The goal of this review was to improve the care of these patients by describing key aspects that all prescribers will need to master in order to optimize outcomes.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 3%
Unknown 36 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 19%
Student > Bachelor 5 14%
Student > Ph. D. Student 3 8%
Professor > Associate Professor 3 8%
Other 3 8%
Other 10 27%
Unknown 6 16%
Readers by discipline Count As %
Medicine and Dentistry 14 38%
Agricultural and Biological Sciences 6 16%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Biochemistry, Genetics and Molecular Biology 2 5%
Neuroscience 1 3%
Other 3 8%
Unknown 9 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 July 2020.
All research outputs
#9,820,583
of 16,649,395 outputs
Outputs from Drug Design, Development and Therapy
#526
of 1,649 outputs
Outputs of similar age
#128,854
of 267,009 outputs
Outputs of similar age from Drug Design, Development and Therapy
#22
of 79 outputs
Altmetric has tracked 16,649,395 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,649 research outputs from this source. They receive a mean Attention Score of 4.9. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,009 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 79 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.